WEST CHESTER, Ohio, Nov 24, 2008 (BUSINESS WIRE) -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in
cardiac surgical ablation systems, today announced that David J.
Drachman, President and Chief Executive Officer, will present at the 20th
Annual Piper Jaffray Health Care Conference at the New York Palace Hotel
in New York City on Wednesday, December 3, 2008 at 11:30 a.m. Eastern
Time.
A live audio webcast and replay of the presenta...
3rd Quarter Highlights
Consolidated revenues of $14.8 million - 23% growth
Record revenues for domestic MIS of $5.7 million - 63% growth
Record international revenues of $2.4 million - 29% growth
Net loss improves 32% to $1.8 million
Initiated EXCLUDE clinical trial
WEST CHESTER, Ohio--(BUSINESS WIRE)--Nov. 4, 2008--AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac
surgical ablation systems, ...
WEST CHESTER, Ohio--(BUSINESS WIRE)--Oct. 31, 2008--AtriCure, Inc.
(Nasdaq: ATRC), received a letter on October 27, 2008 from the U.S.
Department of Justice-Civil Division (the "DOJ") informing the Company
that the DOJ is conducting an investigation for potential False Claims
Act and common law violations relating to the Company's surgical
ablation devices. Specifically, the letter states that the DOJ is
investigating the Company's marketing practices utilized in connection
with its s...
WEST CHESTER, Ohio, Oct. 6 /PRNewswire-FirstCall/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical
ablation products, will release its financial results for the third quarter
ended September 30, 2008 on Tuesday, November 4, 2008.
AtriCure will host a conference call at 10:00 a.m. Eastern Time on
Tuesday, November 4, 2008 to discuss its third quarter 2008 financial results.
A live web cast of the conference call will be available online fro...
WEST CHESTER, Ohio--(BUSINESS WIRE)--
AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a
leader in cardiac surgical ablation systems, today announced that
David J. Drachman, President and Chief Executive Officer, is scheduled
to present at the Third Annual JMP Securities Healthcare Focus
Conference at Le Parker Meridien Hotel in New York City on October 6
at 9:30 a.m. Eastern Time.
A live webcast and recording of the presentation will be available
for 30 days follo...
WEST CHESTER, Ohio, Aug. 25 /PRNewswire-FirstCall/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical
ablation systems, today announced that it will present at the following
investor conferences during September:
-- The Thomas Weisel Partners Healthcare Conference at the Four Seasons
Hotel in Boston on Wednesday, September 3, 2008. David J. Drachman, President
and Chief Executive Officer, is scheduled to present at 10:55 a.m. Eastern
time.
...
Highlights
Record consolidated revenues of $14.9 million
Record revenues from domestic MIS products - $5.1 million
Record international revenues of $2.3 million - 49% growth
Net loss improves 43% to $1.6 million
Secured $10 million credit facility - expands capital resources
Reported MIS procedure times of 60 minutes and hospital stays of two
days or less
WEST CHESTER, Ohio, Aug. ...
WEST CHESTER, Ohio, July 31 /PRNewswire-FirstCall/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical
ablation systems, today announced that it will present at the following
investor conferences during August:
The BMO Focus on Healthcare Conference, Wednesday, August 6, 2008 at
the Millennium Broadway Hotel in New York. David J. Drachman, President
and Chief Executive Officer, is scheduled to present at 9:00 a.m.
Eas...
WEST CHESTER, Ohio, July 10 /PRNewswire-FirstCall/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical
ablation products, will release its financial results for the second quarter
ended June 30, 2008 on Tuesday, August 5, 2008.
AtriCure will host a conference call at 10:00 a.m. ET on Tuesday, August
5, 2008 to discuss second quarter 2008 results. A live web cast of the
conference call will be available online from the investor relations page ...
WEST CHESTER, Ohio, June 20, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical
ablation systems, today announced that its minimally invasive platform was
highlighted during Cardiostim, a world congress in cardiac electrophysiology
and cardiac techniques. On June 18, Dr. Kenneth Ellenbogen, Vice Chairman of
Cardiology and Director of Clinical Cardiac Electrophysiology and Pacing at
the Medical Coll...
WEST CHESTER, Ohio, June 17 /PRNewswire-FirstCall/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical
ablation systems, today announced that David J. Drachman, President and Chief
Executive Officer, is scheduled to present at the Jefferies 2nd Annual
Healthcare Conference in New York City on June 26 at 12:30 p.m. ET.
A webcast recording of the presentation will be available for 30 days
following the presentation on AtriCure's Investor Relati...
Highlights
Record consolidated revenues of $13.5 million - up 26% over 2007
Record revenues from minimally invasive products - $4.9 million - up
65%
Record number of minimally invasive procedures performed in 92 U.S.
centers
Release of Coolrail(TM) linear ablation device and ORLab(TM) mapping
system
WEST CHESTER, Ohio, May 6 /PRNewswire-FirstCall/ -- AtriCure, Inc.
(Nasdaq: ATRC), a med...
WEST CHESTER, Ohio, April 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical
ablation products, will release its financial results for the first quarter
ended March 31, 2008 on Tuesday, May 6, 2008.
AtriCure will host a conference call at 10:00 a.m. ET on Tuesday, May 6,
2008 to discuss first quarter 2008 results. A live web cast of the conference
call will be available online from the investor...
First Case Performed Using Coolrail(TM) Pen in Combination with AtriCure's ORLab(TM) System - Expands Minimally Invasive Ablation Procedure
WEST CHESTER, Ohio, March 18 /PRNewswire-FirstCall/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and leader in cardiac surgical
ablation systems, today announced that its Coolrail(TM) linear ablation pen
received 510(k) clearance from the FDA for the ablation of cardiac tissue.
Additionally, the first patient was successfully treated...
WEST CHESTER, Ohio, Feb 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical
ablation systems, today announced its participation at the upcoming Rodman &
Renshaw "Straight to the Heart" conference at the Boston Harbor Hotel on
Tuesday, March 4, 2008. Attendance at the conference is by invitation only.
The conference format is comprised of one-on-one meetings with no large group
presentations sche...
Highlights
Record 2007 revenues of $48.3 million - up 26% over 2006
Record 2007 domestic open-heart revenues of $27.3 million - up 18%
Record 2007 minimally invasive product revenues of $14.4 million -
up 31%
Record 2007 international revenues of $6.6 million - up 58%
Fourth quarter 2007 net loss narrows to record low of $1.6 million
ABLATE clini...
WEST CHESTER, Ohio, Feb. 12 /PRNewswire-FirstCall/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical
ablation products, announced today that David J. Drachman, President and Chief
Executive Officer, is scheduled to present at the Roth Capital Partners 20th
Annual OC Growth Stock Conference at the Ritz Carlton Laguna Niguel in Dana
Point, California on Wednesday, February 20th at 2:00 p.m. PT.
A live web cast and recording of the presentatio...
WEST CHESTER, Ohio, Feb. 11 /PRNewswire-FirstCall/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical
ablation products, today announced that the first patient was successfully
treated in AtriCure's ABLATE clinical trial. Dr. Richard Kaplon, a well-known
cardiac surgeon, performed the procedure at Mercy General Hospital in
Sacramento, California.
The purpose of the ABLATE clinical trial is to evaluate the safety and
effectiveness of AtriCur...
WEST CHESTER, Ohio, Feb. 7 /PRNewswire-FirstCall/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical
ablation products, announced today the appointment of Mark A. Collar to the
Company's Board of Directors. Mr. Collar recently retired from a distinguished
career with The Procter & Gamble Company, including recently serving as
President of the Global Pharmaceuticals and Personal Health business.
"We are pleased to add Mark to the Board of Dir...
WEST CHESTER, Ohio, Feb. 5 /PRNewswire-FirstCall/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical
ablation products, will release its financial results for the fourth quarter
and full year ended December 31, 2007 on Thursday, February 14, 2008.
AtriCure will host a conference call at 10:00 a.m. ET on Thursday,
February 14, 2008 to discuss fourth quarter and full year 2007 results. A live
web cast of the conference call will be available o...
WEST CHESTER, Ohio, Jan. 14 /PRNewswire-FirstCall/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical
ablation products, today announced recently published results that report on
AtriCure's proprietary minimally invasive products, which physicians have
adopted to treat atrial fibrillation (AF). The results were published in the
Journal of Interventional Cardiac Electrophysiology by two prominent cardiac
surgeons, Dr. James R. Edgerton and Dr. Mi...
WEST CHESTER, Ohio, Jan. 7 /PRNewswire-FirstCall/ -- AtriCure, Inc.
(Nasdaq: ATRC), a medical device company and a leader in cardiac surgical
ablation products, today announced that results reporting on the Company's
proprietary minimally invasive products, which physicians have adopted to
treat atrial fibrillation (AF), were published in The Annals of Thoracic
Surgery by Dr. James H. Wudel, a prominent cardiac surgeon, and colleagues
from the Nebraska Heart Hospital, Lincoln, Nebraska...
